8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Feb 26, 2026·SEC
OPKO Health, Inc.(OPK)Earnings, Financials & Key Ratios
OPK•NASDAQ
$1.50
Price updated Jul 6, 2026
AboutOPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.Show more
- Revenue$607M-14.9%
- EBITDA-$127M-136.3%
- Net Income-$226M-324.1%
- EPS (Diluted)-0.30-291.1%
- Gross Margin21.1%-51.6%
- EBITDA Margin-20.99%-177.7%
- Operating Margin-36.08%-69.2%
- Net Margin-37.2%-398.4%
- ROE-17.14%-343.6%
OPK Price & Volume
OPKO Health, Inc. (OPK) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Operational Profitability Outlook
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Persistent Diagnostic Revenue Erosion
Key Thesis Takeaways
- OPKO Health faces a challenging fundamental outlook characterized by a sustained 17.2% year-over-year revenue decline as of 2026Q1 and persistent difficulty in achieving consistent operating profitability.
- While the company maintains a current ratio of 3.61, the reliance on non-cash accounting adjustments to mask operational losses and the presence of $482.3 million in goodwill create significant valuation uncertainty.
- Investors should remain cautious as the firm continues to burn cash, evidenced by a -17.0% free cash flow margin, while simultaneously allocating capital toward share repurchases.
Verdict Logic
the company's inability to generate positive free cash flow, coupled with a -41.1% operating margin and a persistent 17.2% revenue decline, suggests significant ongoing operational risk.
OPK Growth Metrics
OPKO Health, Inc. (OPK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.13%
5 Years-15.82%
3 Years-15.45%
TTM-15.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-446.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-369.19%
Return on Capital
10 Years-7.04%
5 Years-7.64%
3 Years-9.28%
Last Year-11.55%
OPK Recent Earnings
OPKO Health, Inc. (OPK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
$124M-4.8%
$131M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
$149M+6.3%
$140M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.03+250.0%
$0.02
Rev
$152M+8.5%
$140M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.19-58.3%
$0.12
Rev
$157M-5.4%
$166M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.07vs $0.07+0.0% | $124Mvs $131M-4.8% |
| Q1 2026 | Feb 26, 2026 | $0.04vs $0.07+42.9% | $149Mvs $140M+6.3% |
| Q4 2025 | Oct 29, 2025 | $0.03vs $0.02+250.0% | $152Mvs $140M+8.5% |
| Q3 2025 | Jul 31, 2025 | $0.19vs $0.12-58.3% | $157Mvs $166M-5.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for OPKO Health, Inc. (OPK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.50 | $1.13B | -5.00 | -14.9% | -37.2% | -17.14% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $34.13 | $1.38B | 28.68 | 27.37% | 6.35% | 29.49% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $284.39 | $23.41B | 27.19 | 7.25% | 6.66% | 10.89% | — | |
| $213.45 | $23.63B | 24.39 | 11.78% | 9.08% | 13.8% | — |
Compare OPK vs Peers
OPKO Health, Inc. (OPK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OPK SEC Filings & Documents
OPKO Health, Inc. (OPK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OPK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OPK Frequently Asked Questions
OPKO Health, Inc. (OPK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is OPKO Health, Inc.'s revenue?
OPKO Health, Inc. (OPK) reported $581.2M in revenue for fiscal year 2025. This represents a 581072% increase from $0.1M in 1996.
How fast is OPKO Health, Inc. growing?
OPKO Health, Inc. (OPK) saw revenue decline by 14.9% over the past year.
Is OPK profitable?
OPKO Health, Inc. (OPK) reported a net loss of $213.0M for fiscal year 2025.
Dividend & Returns
What is OPK's return on equity?
OPKO Health, Inc. (OPK) has a return on equity (ROE) of -17.1%. Negative ROE indicates the company is unprofitable.
What is OPKO Health, Inc.'s free cash flow?
OPKO Health, Inc. (OPK) had negative free cash flow of $174.2M in fiscal year 2025, likely due to heavy capital investments.